[Influence of perhexilinmaleat on the exercise electrocardiogram (author's transl)].
In 15 patients with angiographically proven coronary heart disease and reproducible exercise induced ischemic ST-segment depression the antianginal effect of Perhexilinmaleat was tested in a cross-over randomized double-blind trial. The patients were treated 4 weeks with a placebo, 2 weeks with 200 mg and 2 weeks with 400 mg/day Perhexilinmaleat. The exercise-induced ischemic ST-segment depression was significantly reduced (p less than 0.001) by Perhexilinmaleat. This calcium-antagonist drug also prolonged the PQ-interval and reduced the heart rate during exercise. Some liver specific enzymes were slightly elevated. These and other side effects more often occurred at the higher dose of 400 mg/day.
D003327:Coronary Disease / Q000188:drug therapy*; D004562:Electrocardiography; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D008297:Male; D010480:Perhexiline / Q000627:therapeutic use*; D005082:Physical Exertion; D010880:Piperidines / Q000627:therapeutic use*
D010880:Piperidines; D010480:Perhexiline
Wirkung von Perhexilinmaleat auf das Belastungs-Ekg von Patienten mit koronarer Herzerkrankung.